Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 4/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679144 | 0.95 | FOLH1 (0.44) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29678960 | 0.95 | FOLH1 (0.45) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29679075 | 0.94 | FOLH1 (0.44) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29678849 | 0.92 | FOLH1 (0.54) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29679163 | 0.92 | FOLH1 (0.54) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29335236 | 0.92 | FOLH1 (0.54) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL30971343 | 0.92 | FOLH1 (0.54) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29679232 | 0.92 | FOLH1 (0.45) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29679034 | 0.91 | KMT2A (0.43) | FOLH1ATMKMT2AMEN1TLR2 | |
| SCHEMBL29678956 | 0.91 | FOLH1 (0.43) | FOLH1ATMKMT2AMEN1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2023-03-09 | — | — | US | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, AR, SHBG | FOLH1 43/4885ATM 2227/4885KMT2A 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.